科前生物(688526)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
华泰证券 2024-01-28 买入
招商证券 2024-01-19 买入
  盈利预测
据科前生物三季报分析:

  盈利能力维持稳定,主营获利能力保持稳定

  成长能力明显改善,营业收入由亏转盈

  偿债能力维持稳定,偿还流动负债能力很强

  运营能力维持稳定,应收账款周转速度需加快

  现金流能力维持稳定,可持续经营能力加倍增强

  财务数据
    截至第三季度实现净利润3.57亿元,每股收益0.77元。

    截至第三季度最新股东权益376761.48万元,未分配利润189620.25万元。

    截至第三季度最新总资产473774.37万元,负债97012.89万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入827,439,173.94531,839,356.71279,514,834.181,001,267,679.9
营业总成本407,570,296.65263,731,462.07126,626,151.45536,985,629.09
营业利润412,743,443.37276,689,466.17157,887,496.12466,714,448.1
利润总额411,654,477.45275,005,589.86156,199,066.47466,607,801.37
净利润357,180,085.48238,976,717.5135,431,910.74409,147,115.22
其他综合收益----
综合收益总额357,180,085.48238,976,717.5135,431,910.74409,147,115.22
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计2,973,386,605.592,794,077,981.52,789,484,081.942,560,904,694.74
非流动资产合计1,764,357,049.251,737,438,733.791,882,751,478.841,829,737,097.18
资产总计4,737,743,654.844,531,516,715.294,672,235,560.784,390,641,791.92
流动负债合计845,705,990.93725,283,757.57769,539,959.37623,841,368.92
非流动负债合计124,422,903.64156,821,565.43268,249,500.44267,786,232.77
负债合计970,128,894.57882,105,3231,037,789,459.81891,627,601.69
归属于母公司股东权益合计3,765,793,758.43,647,531,472.523,632,482,191.153,496,945,092.74
股东权益合计3,767,614,760.273,649,411,392.293,634,446,100.973,499,014,190.23
负债和股东权益合计4,737,743,654.844,531,516,715.294,672,235,560.784,390,641,791.92
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计910,354,099.44553,229,405.97358,807,595.18988,175,491.31
经营活动现金流出小计464,708,550.15331,765,669.62180,704,258.57564,466,768.34
经营活动产生的现金流量净额445,645,549.29221,463,736.35178,103,336.61423,708,722.97
投资活动现金流入小计918,287,031.32529,467,209.98284,912,353.77913,934,851.03
投资活动现金流出小计1,103,959,733.45746,817,039.36305,720,117.591,551,062,174.32
投资活动产生的现金流量净额-185,672,702.13-217,349,829.38-20,807,763.82-637,127,323.29
筹资活动现金流入小计260,000,000165,000,000115,000,000299,455,637.88
筹资活动现金流出小计315,061,968.21208,180,146.782,018,730.78185,931,114.74
筹资活动产生的现金流量净额-55,061,968.21-43,180,146.78112,981,269.22113,524,523.14
汇率变动对现金及现金等价物的影响----
现金及现金等价物净增加额204,910,878.95-39,066,239.81270,276,842.01-99,894,077.18
期末现金及现金等价物余额655,612,334.08411,635,215.32720,978,297.14450,701,455.13
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润3.57亿元,每股收益0.77元。

    截至第三季度最新股东权益376761.48万元,未分配利润189620.25万元。

    截至第三季度最新总资产473774.37万元,负债97012.89万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入827,439,173.94531,839,356.71279,514,834.181,001,267,679.9
营业总成本407,570,296.65263,731,462.07126,626,151.45536,985,629.09
营业利润412,743,443.37276,689,466.17157,887,496.12466,714,448.1
利润总额411,654,477.45275,005,589.86156,199,066.47466,607,801.37
净利润357,180,085.48238,976,717.5135,431,910.74409,147,115.22
其他综合收益----
综合收益总额357,180,085.48238,976,717.5135,431,910.74409,147,115.22
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计2,973,386,605.592,794,077,981.52,789,484,081.942,560,904,694.74
非流动资产合计1,764,357,049.251,737,438,733.791,882,751,478.841,829,737,097.18
资产总计4,737,743,654.844,531,516,715.294,672,235,560.784,390,641,791.92
流动负债合计845,705,990.93725,283,757.57769,539,959.37623,841,368.92
非流动负债合计124,422,903.64156,821,565.43268,249,500.44267,786,232.77
负债合计970,128,894.57882,105,3231,037,789,459.81891,627,601.69
归属于母公司股东权益合计3,765,793,758.43,647,531,472.523,632,482,191.153,496,945,092.74
股东权益合计3,767,614,760.273,649,411,392.293,634,446,100.973,499,014,190.23
负债和股东权益合计4,737,743,654.844,531,516,715.294,672,235,560.784,390,641,791.92
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计910,354,099.44553,229,405.97358,807,595.18988,175,491.31
经营活动现金流出小计464,708,550.15331,765,669.62180,704,258.57564,466,768.34
经营活动产生的现金流量净额445,645,549.29221,463,736.35178,103,336.61423,708,722.97
投资活动现金流入小计918,287,031.32529,467,209.98284,912,353.77913,934,851.03
投资活动现金流出小计1,103,959,733.45746,817,039.36305,720,117.591,551,062,174.32
投资活动产生的现金流量净额-185,672,702.13-217,349,829.38-20,807,763.82-637,127,323.29
筹资活动现金流入小计260,000,000165,000,000115,000,000299,455,637.88
筹资活动现金流出小计315,061,968.21208,180,146.782,018,730.78185,931,114.74
筹资活动产生的现金流量净额-55,061,968.21-43,180,146.78112,981,269.22113,524,523.14
汇率变动对现金及现金等价物的影响----
现金及现金等价物净增加额204,910,878.95-39,066,239.81270,276,842.01-99,894,077.18
期末现金及现金等价物余额655,612,334.08411,635,215.32720,978,297.14450,701,455.13
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
武汉华中农大资产经营有限公司7800.4316.737800.43
陈焕春7086.0515.207086.05
金梅林3667.787.873667.78
吴斌3317.337.123317.33
何启盖3317.337.123317.33
方六荣3317.337.123317.33
吴美洲2858.626.132858.62
叶长发2750.615.902750.61
北京源峰私募基金管理合伙企业(有限合伙)-源峰价值私募证券投资基金399.600.864.84
香港中央结算有限公司310.430.6791.06
  主力控盘
  公司简介
科前生物 所属地域: 湖北省 涉及概念: 禽流感,宠物经济,沪股通,融资融券,动物疫苗
主营业务: 一般项目:生物制品的开发、研制;动物传染病诊断咨询及技术服务;兽药生产、销售(凭许可证在核定期限内经营);货物进出口、技术进出口、代理进出口(不含国家禁止或限制进出口的货物或技术);实验分析仪器销售;专用化学产品销售(不含危险化学品)(除依法须经批准的项目外,凭营业执照依法自主开展经营活动)
上市日期: 2020-09-22 每股净资产: 8.08元 每股收益: 0.77元 净利润: 3.57亿元 净利润增长率: 26.11%
营业收入: 8.27亿元 每股现金流: 0.96元 每股公积金: 2.43元 每股未分配利润: 4.07元 总股本: 4.66亿 流通股: 2.42亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心